Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

5(83.3%)

N/A

1(16.7%)

6Total

Phase 1(5)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02821338Phase 1Completed

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

Role: collaborator

NCT03559751Phase 1Completed

Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes

Role: collaborator

NCT03559725Phase 1Completed

Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes

Role: collaborator

NCT03170674Not ApplicableCompleted

CSD170501: Study to Assess Biomarkers of Tobacco Exposure in Smokers During In-Clinic Confinement Switch to an Electronic Cigarette

Role: collaborator

NCT02572089Phase 1Completed

Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers

Role: collaborator

NCT01898676Phase 1Unknown

A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets

Role: lead

All 6 trials loaded